Press Releases

igc-ad1 igc pharma
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients
Read More →
igc-ad1
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
Read More →
igc pharma
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
Read More →
clincloud
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Read More →
igc-ad1 igc pharma
IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Read More →
alzheimer igc pharma
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain
Read More →
igc-ad1 igc pharma
Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients
Read More →
igc pharma
IGC Reports Financial Results for December 31, 2020 Quarter
Read More →
igc pharma
IGC Announces Results of its 2020 Annual Shareholders Meeting
Read More →
igc pharma
IGC Nominates Mr. John E. Lynch to Its Board of Directors
Read More →
igc pharma
IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →
igc-ad1 igc pharma
IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →
igc-ad1
IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →
clincloud
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s
Read More →
artificial intelligence igc pharma
IGC Filed a Patent for a New Formulation to Treat Pain
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Receives a Notice of Allowance from the U.S. Patent Office
Read More →